Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Petr Bušek, Jonathan S. Duke‐Cohan, Aleksi Šedo
Cancers (2022) Vol. 14, Iss. 9, pp. 2072-2072
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

How chemokines organize the tumour microenvironment
Thorsten R. Mempel, Julia K. Lill, Lukas M. Altenburger
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 28-50
Closed Access | Times Cited: 95
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Jisha Pillai U, Anindita Ray, Meenu Maan, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103684-103684
Closed Access | Times Cited: 18
The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review
Anoosha Niazmand, Reza Nedaeinia, Nasimeh Vatandoost, et al.
Gene (2024) Vol. 927, pp. 148659-148659
Open Access | Times Cited: 5
Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
Xiaopeng Hu, Xisheng Wang, Xingkui Xue
Molecules (2022) Vol. 27, Iss. 14, pp. 4498-4498
Open Access | Times Cited: 20
Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review
Valentin Petrov, Teodora Aleksandrova, Aleksandar Pashev
Molecules (2025) Vol. 30, Iss. 5, pp. 1043-1043
Open Access
Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease
Xiabo Wang, Zhongqun Wang, Jianqiang He
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 165-192
Open Access | Times Cited: 3
Incretin-Based Therapies and Cancer: What’s New?
Sanja Medenica, Jelena Bogdanović, Jelena Vekić, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 678-678
Open Access
Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis
Ahmed S. Kenawy, Yi‐Shao Liu, Ayobami Adesoji Aiyeolemi, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
Elevated activity of plasma dipeptidyl peptidase 4 upon stress can be targeted to reverse tumor immunosuppression
Peipei Li, Mei Liang, Junlin Zhu, et al.
Pharmacological Research (2025) Vol. 215, pp. 107696-107696
Open Access
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
Richeek Pradhan, Oriana Hoi Yun Yu, Robert W. Platt, et al.
BMJ Open Diabetes Research & Care (2023) Vol. 11, Iss. 6, pp. e003550-e003550
Open Access | Times Cited: 9
Metformin as a promising target for DPP4 expression: computational modeling and experimental validation
Amr Ahmed El–Arabey, Haiyan Zhang, Mohnad Abdalla, et al.
Medical Oncology (2023) Vol. 40, Iss. 10
Open Access | Times Cited: 8
Glucagon Like Peptide‐1 Receptor Agonists and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population‐Based Cohort Study
Richeek Pradhan, Oriana Hoi Yun Yu, Robert W. Platt, et al.
Diabetic Medicine (2023) Vol. 41, Iss. 4
Open Access | Times Cited: 5
Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 11, pp. 3022-3034
Open Access | Times Cited: 8
Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases
Marija Drakul, Miodrag Čolić
European Journal of Immunology (2023) Vol. 53, Iss. 12
Open Access | Times Cited: 4
Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review
Angelika Buczyńska, Maria Kościuszko, Adam Krętowski, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Virtual screening strategy for anti-DPP-IV natural flavonoid derivatives based on machine learning
Gen Lu, Fei Pan, Xiaotong Li, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 13, pp. 6645-6659
Closed Access | Times Cited: 3
Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure
John Gehris, Charlie Ervin, Charlotte Hawkins, et al.
Biochemical Pharmacology (2023) Vol. 219, pp. 115914-115914
Open Access | Times Cited: 3
CD26 and Cancer
Oscar J. Cordero
Cancers (2022) Vol. 14, Iss. 21, pp. 5194-5194
Open Access | Times Cited: 5
Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs
Loretta De Chiara, Leticia Barcia-Castro, María Gallardo‐Gómez, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4563-4563
Open Access | Times Cited: 4
Sitagliptin Induces Tolerogenic Human Dendritic Cells
Marija Drakul, Sergej Tomić, Marina Bekić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16829-16829
Open Access | Times Cited: 2
Redirection to the Drug Discovery: Antidiabetic Drugs Repurposing in Cancer
Prajakta Bule, Tejaswini Kolipaka, Shital Ranvare, et al.
Drug repurposing (2024), pp. 217-248
Closed Access
Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies
Maryam Bayanati, Mohammad Rabbani, Shirin Sirous Kabiri, et al.
Deleted Journal (2024) Vol. 23, Iss. 1
Open Access
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1479-1479
Open Access
Dipeptidyl peptidase IV: a multifunctional enzyme with implications in several pathologies including cancer
Yarini Arrebola Sánchez, Fabiola Almeida García, Daniel Ojeda del Sol, et al.
Physical Sciences Reviews (2023) Vol. 9, Iss. 8, pp. 2541-2596
Closed Access | Times Cited: 1
Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin‐Hsiao Tseng
Cancers (2023) Vol. 15, Iss. 17, pp. 4276-4276
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top